Literature DB >> 34875340

Breaking barriers: Neurodegenerative repercussions of radiotherapy induced damage on the blood-brain and blood-tumor barrier.

Barrett D Allen1, Charles L Limoli2.   

Abstract

Exposure to radiation during the treatment of CNS tumors leads to detrimental damage of the blood brain barrier (BBB) in normal tissue. Effects are characterized by leakage of the vasculature which exposes the brain to a host of neurotoxic agents potentially leading to white matter necrosis, parenchymal calcification, and an increased chance of stroke. Vasculature of the blood tumor barrier (BTB) is irregular leading to poorly perfused and hypoxic tissue throughout the tumor that becomes resistant to radiation. While current clinical applications of cranial radiotherapy use dose fractionation to reduce normal tissue damage, these treatments still cause significant alterations to the cells that make up the neurovascular unit of the BBB and BTB. Damage to the vasculature manifests as reduction in tight junction proteins, alterations to membrane transporters, impaired cell signaling, apoptosis, and cellular senescence. While radiotherapy treatments are detrimental to normal tissue, adapting combined strategies with radiation targeted to damage the BTB could aid in drug delivery. Understanding differences between the BBB and the BTB may provide valuable insight allowing clinicians to improve treatment outcomes. Leveraging this information should allow advances in the development of therapeutic modalities that will protect the normal tissue while simultaneously improving CNS tumor treatments.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Blood brain barrier; Blood tumor barrier; Neurovascular unit; Radiation

Mesh:

Year:  2021        PMID: 34875340      PMCID: PMC8925982          DOI: 10.1016/j.freeradbiomed.2021.12.002

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  188 in total

1.  Ultra-fast magnetic resonance encephalography of physiological brain activity - Glymphatic pulsation mechanisms?

Authors:  Vesa Kiviniemi; Xindi Wang; Vesa Korhonen; Tuija Keinänen; Timo Tuovinen; Joonas Autio; Pierre LeVan; Shella Keilholz; Yu-Feng Zang; Jürgen Hennig; Maiken Nedergaard
Journal:  J Cereb Blood Flow Metab       Date:  2015-12-21       Impact factor: 6.200

2.  A partially inactivating mutation in the sodium-dependent lysophosphatidylcholine transporter MFSD2A causes a non-lethal microcephaly syndrome.

Authors:  Vafa Alakbarzade; Abdul Hameed; Debra Q Y Quek; Barry A Chioza; Emma L Baple; Amaury Cazenave-Gassiot; Long N Nguyen; Markus R Wenk; Arshia Q Ahmad; Ajith Sreekantan-Nair; Michael N Weedon; Phil Rich; Michael A Patton; Thomas T Warner; David L Silver; Andrew H Crosby
Journal:  Nat Genet       Date:  2015-05-25       Impact factor: 38.330

Review 3.  Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.

Authors:  Jason M Lajoie; Eric V Shusta
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-08       Impact factor: 13.820

Review 4.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.

Authors:  Dai Fukumura; Jonas Kloepper; Zohreh Amoozgar; Dan G Duda; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2018-03-06       Impact factor: 66.675

5.  Nonclinical Safety and Toxicokinetics of MnTnBuOE-2-PyP5+ (BMX-001).

Authors:  Shayne Cox Gad; Dexter W Sullivan; Ivan Spasojevic; Cesar V Mujer; Charles B Spainhour; James D Crapo
Journal:  Int J Toxicol       Date:  2016-04-20       Impact factor: 2.032

6.  VEGFR-2 expression in brain injury: its distribution related to brain-blood barrier markers.

Authors:  J V Lafuente; E G Argandoña; B Mitre
Journal:  J Neural Transm (Vienna)       Date:  2006-04       Impact factor: 3.575

7.  ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases.

Authors:  Priya Kumthekar; Shou-Ching Tang; Andrew J Brenner; Santosh Kesari; David E Piccioni; Carey Anders; Jose Carrillo; Pavani Chalasani; Peter Kabos; Shannon Puhalla; Katherine Tkaczuk; Agustin A Garcia; Manmeet S Ahluwalia; Jeffrey S Wefel; Nehal Lakhani; Nuhad Ibrahim
Journal:  Clin Cancer Res       Date:  2020-01-22       Impact factor: 12.531

8.  Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.

Authors:  Tetsuichiro Inai; Michael Mancuso; Hiroya Hashizume; Fabienne Baffert; Amy Haskell; Peter Baluk; Dana D Hu-Lowe; David R Shalinsky; Gavin Thurston; George D Yancopoulos; Donald M McDonald
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

Review 9.  Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas.

Authors:  Michael Weaver; Douglas W Laske
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

10.  Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis.

Authors:  J Strugar; D Rothbart; W Harrington; G R Criscuolo
Journal:  J Neurosurg       Date:  1994-10       Impact factor: 5.115

View more
  2 in total

Review 1.  Emerging Biomarkers for Immunotherapy in Glioblastoma.

Authors:  Nadia Mensali; Else Marit Inderberg
Journal:  Cancers (Basel)       Date:  2022-04-12       Impact factor: 6.575

2.  The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.

Authors:  Mika L Persson; Alicia M Douglas; Frank Alvaro; Pouya Faridi; Martin R Larsen; Marta M Alonso; Nicholas A Vitanza; Matthew D Dun
Journal:  Neuro Oncol       Date:  2022-09-01       Impact factor: 13.029

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.